Acrivon’s Generative Phosphoproteomics AP3 Platform Accelerates Pathway-Based Drug Design & Enables Rapid Clinical Translation
- Discuss the development of a computational pipeline and supporting infrastructure to analyze large-scale phosphoproteomics datasets and systematically characterize drug-regulated signaling network dynamics
- Applying a proprietary generative AI model to predict kinase–substrate relationships, enabling deeper pathway interrogation
- Utilizing these approaches to define differentiated AP3 drug response profiles and facilitate the identification of predictive biomarkers to support patient stratification and translational applications